224 related articles for article (PubMed ID: 25275415)
41. Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Reske SN; Winter G; Baur B; Machulla HJ; Kull T
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):969-70. PubMed ID: 23558687
[No Abstract] [Full Text] [Related]
42. Rectal Carcinoma on 68Ga-PSMA PET/CT.
Huang YT; Fong W; Thomas P
Clin Nucl Med; 2016 Mar; 41(3):e167-8. PubMed ID: 26571447
[TBL] [Abstract][Full Text] [Related]
43. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
44. Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT.
Chan M; Hsiao E
Clin Nucl Med; 2017 Feb; 42(2):110-111. PubMed ID: 27997426
[TBL] [Abstract][Full Text] [Related]
45. 68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue.
Ferraro DA; Rupp NJ; Donati OF; Messerli M; Eberli D; Burger IA
Clin Nucl Med; 2019 Apr; 44(4):e291-e293. PubMed ID: 30688746
[TBL] [Abstract][Full Text] [Related]
46. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
47. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
48. 68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI.
Muehlematter UJ; Rupp NJ; Mueller J; Eberli D; Burger IA
Clin Nucl Med; 2018 Aug; 43(8):e282-e284. PubMed ID: 29847319
[TBL] [Abstract][Full Text] [Related]
49. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
[TBL] [Abstract][Full Text] [Related]
50.
Sathekge M; Lengana T; Modiselle M; Vorster M; Zeevaart J; Maes A; Ebenhan T; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):689-694. PubMed ID: 27822700
[TBL] [Abstract][Full Text] [Related]
51.
van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
[No Abstract] [Full Text] [Related]
52. Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.
Kanthan GL; Coyle L; Kneebone A; Schembri GP; Hsiao E
Clin Nucl Med; 2016 Jun; 41(6):500-1. PubMed ID: 26914565
[TBL] [Abstract][Full Text] [Related]
53. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
54. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
55. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
56. Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.
Kobe C; Maintz D; Fischer T; Drzezga A; Chang DH
Clin Nucl Med; 2015 Nov; 40(11):897-8. PubMed ID: 26018688
[TBL] [Abstract][Full Text] [Related]
57. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
Baranski AC; Schäfer M; Bauder-Wüst U; Roscher M; Schmidt J; Stenau E; Simpfendörfer T; Teber D; Maier-Hein L; Hadaschik B; Haberkorn U; Eder M; Kopka K
J Nucl Med; 2018 Apr; 59(4):639-645. PubMed ID: 29191856
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
59. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
60. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
